CAR-T cell therapy in plain language, from collection day to the months after

CAR-T cell therapy takes a patient's own T cells, a type of white blood cell, and re-engineers them in a factory so they recognize a specific marker on cancer cells. The cells are then infused back, where they multiply and attack. The first CAR-T product, Kymriah (tisagenlecleucel), was approved by the FDA in August 2017 for children and young adults with a form of acute lymphoblastic leukemia that had come back or stopped responding to treatment. Every CAR-T product approved since has also been for a blood cancer.

For patients and families, the first question is usually practical: what happens, and when? So this explainer follows the order of events. Schedules vary between hospitals and products, and the treating team's plan is the one that counts.

The idea in brief

T cells already patrol the body for infected or abnormal cells, but cancers often slip past them. A chimeric antigen receptor, or CAR, is a synthetic receptor assembled from parts of several natural proteins. The outer part, borrowed from an antibody, grabs a chosen target on the cancer cell. The inner parts tell the T cell to switch on and multiply once it has latched on. A disarmed virus carries the CAR gene into the patient's T cells in the lab.

Approved products aim at one of two targets: CD19, found on normal B cells and on many B-cell leukemias and lymphomas, or BCMA, found on myeloma cells.

What is approved

Most approvals are for cancer that has come back or resisted earlier treatment, though some products are now approved after only one prior line of therapy. Labels change, so the FDA's list of approved cellular and gene therapy products is the place to check current uses. The National Cancer Institute has a readable overview of CAR T cells.

The timeline, step by step

Referral and evaluation (often one to three weeks)

An oncologist refers the patient to an authorized treatment center, usually a large academic or cancer hospital. The team checks heart, lung, kidney and liver function, screens for infections, reviews past treatment and seeks insurance approval, which can take time of its own. Patients are asked to line up a caregiver and to plan on staying near the center for a while after infusion.

Collection day (apheresis)

Blood is drawn from one arm, run through a machine that separates out white blood cells, and returned through the other arm or a central line. It usually takes a few hours and feels much like donating platelets. The collected cells are labeled, often frozen, and shipped to the manufacturing site.

Manufacturing (often three to five weeks)

At the plant, T cells are separated out, activated, given the CAR gene and grown until there are enough. The batch is tested for identity, potency and sterility, then frozen and shipped back. Our posts on how a cell therapy is made and on stem cell technology and cryopreservation explain the cleanroom steps and why frozen cells need such careful handling. Occasionally a batch misses its specifications, and the team then discusses options, which can include a second collection.

Bridging therapy (during manufacturing, if needed)

Cancer does not wait for the factory. Many patients receive bridging therapy, which might be chemotherapy, radiation, steroids or targeted drugs, to hold the disease in check until the cells are ready. Some patients need none.

Lymphodepletion (the week before infusion)

A few days before infusion, patients receive a short course of chemotherapy, most often fludarabine and cyclophosphamide over about three days. The aim is not to treat the cancer directly but to lower the number of existing immune cells, which gives the CAR-T cells room to expand.

Infusion day (day 0)

The frozen bag is thawed and infused through a vein, much like a blood transfusion. The infusion itself often takes less than half an hour, and patients usually get acetaminophen and an antihistamine first. Depending on the product and the center, this happens as an inpatient or an outpatient.

The first two weeks

This is the period of closest watch, because the main side effects usually start within days. In June 2025 the FDA ended the REMS programs, the extra safety requirements attached to approved autologous CAR-T products since launch, citing years of experience managing their side effects. Labels now advise patients to stay near a healthcare facility for at least two weeks and to avoid driving for two weeks. Those periods used to be four weeks and eight weeks. Many centers still set their own, sometimes longer, rules.

Weeks to months after

Blood counts can stay low for weeks or longer. CD19 products also wipe out normal B cells, which make antibodies, so some patients receive antibody replacement (immunoglobulin) to lower infection risk. Scans to judge how the cancer responded are often done about one and three months after infusion. Follow-up does not end there: under FDA guidance, products made with viral vectors that insert into the genome come with long-term follow-up that can last up to 15 years.

Side effects, in general terms

Cytokine release syndrome (CRS)

When CAR-T cells multiply and attack, they and other immune cells release signaling proteins called cytokines. The result can look like a severe flu: fever, chills, fatigue, low blood pressure and, in serious cases, low oxygen levels and strain on organs. CRS is the most common serious side effect. Teams grade it and treat it with drugs such as tocilizumab, which blocks a cytokine called IL-6, and steroids.

Neurological effects (ICANS)

Immune effector cell-associated neurotoxicity syndrome can cause confusion, trouble finding words, tremor, changes in handwriting, drowsiness and, less often, seizures or brain swelling. Nurses typically run a short check several times a day: naming objects, writing a sentence, counting backward. Most cases resolve, but some are severe.

Other effects

Low blood counts, infections, and with some BCMA products, delayed neurological problems including movement symptoms resembling parkinsonism. Each product's label lists its risks in detail.

The 2024 boxed warning on secondary T cell cancers

In November 2023 the FDA said it was investigating reports of T cell cancers in patients who had received BCMA- or CD19-directed CAR-T products, including some cancers in which the CAR gene itself was found. In January 2024 it told manufacturers to add a boxed warning, the strongest kind of label warning, and the labels of all six products then on the market carried it by April 2024. The FDA said the overall benefits of these products continue to outweigh their potential risks for their approved uses, and that people who receive them should be monitored for new cancers for life.

Reported cases are rare compared with the number of people treated. Researchers are still sorting out how many are caused by the CAR-T cells and how many reflect earlier chemotherapy or the original cancer.

Cost and access

US list prices for approved CAR-T products run to several hundred thousand dollars for the cells alone, roughly $400,000 to more than $500,000 for recent products. Hospital care, side-effect treatment, travel and lodging come on top. Medicare covers FDA-approved CAR-T for approved uses under a national coverage decision issued in 2019, and most private insurers cover it with prior authorization.

The costs that do not show up on a bill fall on families: a caregiver available around the clock for the first weeks, time off work, and housing near a center that may be hours from home. Many centers and manufacturers run travel and lodging assistance programs. Studies have also found that people who live far from treating centers, and some racial and ethnic minority groups, receive CAR-T less often than their share of eligible patients would predict. Shorter required stays after the 2025 label changes may help some rural patients, though it is too early to know by how much.

What is being tested next

• Earlier use. Trials have moved CAR-T from the last line of treatment to the second line for some lymphomas and for myeloma, and the FDA has approved some of those uses.
• Solid tumors. These are harder: good targets are often also present on healthy tissue, and tumors build defenses that keep T cells out or switch them off. Early results include GD2-directed CAR-T cells in children with neuroblastoma (New England Journal of Medicine, 2023) and in diffuse midline gliomas (Nature, 2024). Two other engineered T cell therapies, not CAR-T, reached FDA approval for solid tumors in 2024: Amtagvi for melanoma and Tecelra for synovial sarcoma.
• Autoimmune disease. A team in Erlangen, Germany, reported in the New England Journal of Medicine in 2024 on 15 people with severe lupus, myositis or systemic sclerosis treated with CD19 CAR-T cells. All the lupus patients reached remission, the others improved markedly, and all stopped their immune-suppressing drugs during a median follow-up of 15 months. Many trials in lupus and other autoimmune diseases have opened since. None of these uses is approved.
• Off-the-shelf cells. Donor T cells, gene edited so they do not attack the recipient, could be made in advance and skip the weeks of waiting.
• CAR-T made inside the body. Researchers are testing ways to deliver the CAR gene straight to T cells in the bloodstream, which would remove the factory step entirely. First human studies are under way.

Most of these trials are small. A listing on ClinicalTrials.gov shows the phase and target enrollment up front, and for CAR-T studies in lupus or solid tumors that usually means phase 1, with a few dozen participants or fewer, testing safety and dose. Our guide to reading a ClinicalTrials.gov listing walks through the fields that tell you how far along a study really is.